歌礼制药宣布其口服小分子GLP-1药物在临床试验中取得积极进展,显示出良好的安全性和药代动力学特征。该药物用于治疗2型糖尿病和肥胖症,具有每日一次给药的优势,目前处于II期临床阶段。研究覆盖多个国际临床中心,初步数据支持进一步开发。
Source Link歌礼制药宣布其口服小分子GLP-1药物在临床试验中取得积极进展,显示出良好的安全性和药代动力学特征。该药物用于治疗2型糖尿病和肥胖症,具有每日一次给药的优势,目前处于II期临床阶段。研究覆盖多个国际临床中心,初步数据支持进一步开发。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.